Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep 30;69(Suppl 2):S245-S254.
doi: 10.33549/physiolres.934512.

Melanocortin pathways: suppressed and stimulated melanocortin-4 receptor (MC4R)

Affiliations
Review

Melanocortin pathways: suppressed and stimulated melanocortin-4 receptor (MC4R)

V Hainer et al. Physiol Res. .

Abstract

Leptin-melanocortin pathway plays an essential role in the body weight regulation. Enhanced melanocortin signaling in the hypothalamus results in both decreased food intake and increased energy expenditure. The discovery of monogenic obesities with dysfunction of melanocortin-4 receptor (MC4R) greatly contributed to understanding of energy balance regulation. This review presents phenotypical characterization and prevalence of the MC4R gene mutations. Genome-wide association studies revealed that MC4R gene is significantly related not only to monogenic obesities but also to common obesity. An interaction of variants in the MC4R gene with fat mass and obesity associated (FTO) gene significantly increases the risk for obesity, particularly in adolescence. On the other hand, about 15 % of the MC4R gene variants result in a gain of function that protects against obesity and is associated with favorable metabolic profile. Long-term attempts to activate the MC4R have recently been finalized by a discovery of setmelanotide, a novel specific MC4R agonist that is devoid of untoward cardiovascular side-effects. The employment of specific MC4R agonists may open new horizons not only in the treatment of rare monogenic obesities but also in some common obesities where stimulation of MC4R could be achieved.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

There is no conflict of interest.

Similar articles

Cited by

References

    1. ADAMSKA-PATRUNO E, GOSICK J, CZAJOWSKI P, MALISZEWSKA K, CIBOROWSKI M, GOLONKO A, WAVRUSIEWICZ-KURYLONEK N, CITKO A, WASZCZENIUK M, KRETOWSKI A, GORSKA M. The MC4R genetic variants are associated with lower visceral fat accumulation and higher postprandial relative increase in carbohydrate utilization in humans. Eur J Nutr. 2019;58:2929–2941. doi: 10.1007/s00394-019-01955-0. - DOI - PMC - PubMed
    1. ALDHOON HAINEROVÁ I, ZAMRAZILOVÁ H, SEDLÁČKOVÁ D, HAINER V. Hypogonadotropic hypogonadism in a homozygous MC4R mutation carrier and the effect of sibutramine treatment on body weight and obesity-related health risks. Obes Facts. 2011;4:324–328. doi: 10.1159/000330763. - DOI - PMC - PubMed
    1. ANDERSON EJ, CAKIR I, CARRINGTON SJ, CONE RD, GHAMARI-LANGROUDI M, GILLYARD T, GIMENEZ LE, LITT MJ. 60 years of POMC: regulation of feeding and energy homeostasis by α-MSH. J Mol Endocrinol. 2016;56:T157–T174. doi: 10.1530/JME-16-0014. - DOI - PMC - PubMed
    1. ASLAN IR, RANDIVE SA, ERSOY BA, ROGERS SJ, LUSTIG RH, VAISSE C. Bariatric surgery in a patient with complete MC4R deficiency. Int J Obes (Lond) 2011;35:457–461. doi: 10.1038/ijo.2010.168. - DOI - PMC - PubMed
    1. AYERS KL, GLICKSBERG BS, GARFIELD AS, LONGERICH S, WHITE JA, YANG P, DU L, CHITTENDEN TW, GULCHER JR, ROY S, FIEDOREK F, GOTTESDIENER K, COHEN S, NORTH KE, SCHADT EE, LI SD, CHEN R, Van der PLOEG LHT. Melanocortin 4 receptor pathway dysfunction in obesity: patient stratification aimed at MC4R agonist treatment. J Clin Endocrinol Metab. 2018;103:2601–2612. doi: 10.1210/jc.2018-00258. - DOI - PMC - PubMed